13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q2 2023 · Filed May 15, 2023 · Accession 0001012975-23-000217
Total Value
$207.2M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | EQRX, INC. | 26886C107 | 36,335,375 | $70.5M | 34.02% |
| 2 | DENALI THERAPEUTICS, INC. | DNLI | 2,568,749 | $59.2M | 28.57% |
| 3 | ERASCA, INC. | ERAS | 11,055,554 | $33.3M | 16.06% |
| 4 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $29.0M | 13.98% |
| 5 | KARUNA THERAPEUTICS, INC. | 48576A100 | 30,000 | $5.4M | 2.63% |
| 6 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R100 | 3,798,926 | $4.6M | 2.22% |
| 7 | NATERA, INC. | NTRA | 64,441 | $3.6M | 1.73% |
| 8 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $1.6M | 0.79% |